sponsored
PatientsVille.com Logo

PatientsVille

Acetylcysteine Medical Research Studies

Up-to-date List of Acetylcysteine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Acetylcysteine Medical Research Studies

Rank Status Study
1 Recruiting N-Acetylcysteine for Tobacco Smoking
Conditions: Tobacco Smoking;   Oxidative Stress;   Inflammation
Intervention: Drug: N-Acetylcysteine
Outcome Measures: The efficacy of N-Acetylcysteine in reducing of the cigarettes per day;   Efficacy of N-Acetylcysteine in reducing exhaled Carbon Monoxide
2 Recruiting N-Acetylcysteine in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Drug: N-Acetylcysteine;   Drug: Placebo
Outcome Measures: The frequency of SCD related pain in daily life in patients with Sickle Cell Disease;   The severity of SCD related pain in daily life;   The incidence and severity of painful crises;   The frequency and length of hospital admissions;   The health-related Quality of Life;   The SCD-related societal costs;   The tolerability of NAC;   Frequency of use of pain medication at home;   Frequency of SCD complications (e.g. acute chest syndrome);   The changes in hematological markers of oxidative stress, hemolysis, hypercoagulability, inflammation, erythrocyte adhesion and endothelial dysfunction
3 Unknown  Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Condition: Radiocontrast-Induced Nephropathy
Interventions: Drug: Acetylcysteine;   Drug: Visipaque 320
Outcome Measures: Changes in renal blood flow;   Changes in glomerular filtration rate, tubular function, oxidative balance.
4 Recruiting N-Acetylcysteine in Intra-amniotic Infection/Inflammation
Conditions: Labor, Premature;   Preterm Premature Rupture of the Membranes;   Infection;   Inflammation;   Chorioamnionitis
Interventions: Procedure: amniocentesis;   Drug: N-Acetylcysteine or placebo
Outcome Measures: early onset neonatal sepsis;   maternal and umbilical cord plasma N-Acetylcysteine levels;   maternal and umbilical cord plasma antioxidant capacity;   maternal and umbilical cord blood glutathione concentration;   umbilical cord levels of inflammatory cytokine concentrations;   funisitis grades;   other neonatal outcomes (respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, late-onset sepsis, bronchopulmonary dysplasia)
5 Recruiting Theophylline, N-Acetylcysteine, and Theophylline Plus N-Acetylcysteine in Preventing Contrast-induced Nephropathy
Condition: Contrast-Induced Nephropathy
Interventions: Drug: N-Acetylcysteine;   Drug: Theophylline;   Drug: 0.9% sodium chloride
Outcome Measure: Plasma creatinine level
6 Recruiting Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents
Condition: Deliberate Self Harm
Interventions: Dietary Supplement: N-Acetylcysteine;   Drug: fMRI
Outcome Measures: Deliberate Self Harm Inventory Clinical Change Version;   K-SADS-PL;   Inventory of Statements about Self-Injury;   Columbia Suicide Severity Rating Scale;   Barrett Impulsivity Scale;   Deliberate Self-Harm Questionnaire-Mood;   BDI-II;   Iowa Gambling Task;   Symptom Check-List 90;   Difficulties in Emotion Regulation Scale
7 Recruiting Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.
Condition: Pyelonephritis
Interventions: Drug: Acetylcysteine;   Drug: placebo Acetylcysteine
Outcome Measures: Serum procalcitonin;   Serum C Reactive Protein;   Leukocyte count;   Probable adverse effects (nausea, vomiting, bad tasting, stomatitis, ...)
8 Unknown  N-Acetylcysteine to Prevent Renal Failure
Conditions: Kidney Failure, Acute;   Oxidative Stress Induction
Interventions: Drug: N-Acetylcysteine;   Drug: Control
Outcome Measures: Decrease in glomerular filtration defined by at least 30% compared to preoperative levels .;   Up 50% of preoperative levels of serum creatinine.;   Death from any cause.;   Need for dialysis;   Cardiovascular morbidity.;   Increased levels of Cystatin C.;   Increased levels of NGAL.;   Increased levels of isoprostane.
9 Not yet recruiting Efficacy Mechanism of N-Acetylcysteine in Patients With Posttraumatic Stress Disorder
Condition: Posttraumatic Stress Disorder
Interventions: Drug: N-Acetylcysteine;   Drug: Placebo
Outcome Measures: Changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach;   Change from baseline in Clinician-administered PTSD scale scores at 1st week;   Change from baseline in Clinician-administered PTSD scale scores at 4th weeks;   Change from baseline in Clinician-administered PTSD scale scores at 8th weeks;   Change from baseline in Hamilton depression rating scale scores at 1st week;   Change from baseline in Hamilton depression rating scale scores at 4th weeks;   Change from baseline in Hamilton depression rating scale scores at 8th weeks;   Change from baseline in Hamilton anxiety rating scale scores at 1st week;   Change from baseline in Hamilton anxiety rating scale scores at 4th weeks;   Change from baseline in Hamilton anxiety rating scale scores at 8th weeks;   Number of participants with adverse events
10 Recruiting Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Conditions: Mucositis;   Oral Complications;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Adenoid Cystic Carcinoma of the Oral Cavity;   Stage I Basal Cell Carcinoma of the Lip;   Stage I Lymphoepithelioma of the Nasopharynx;   Stage I Lymphoepithelioma of the Oropharynx;   Stage I Mucoepidermoid Carcinoma of the Oral Cavity;   Stage I Salivary Gland Cancer;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Nasopharynx;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Adenoid Cystic Carcinoma of the Oral Cavity;   Stage II Basal Cell Carcinoma of the Lip;   Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Lymphoepithelioma of the Oropharynx;   Stage II Mucoepidermoid Carcinoma of the Oral Cavity;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: Acetylcysteine;   Other: placebo;   Other: quality-of-life assessment;   Other: questionnaire administration
Outcome Measures: Area under the curve (AUC) of the GRIX sticky saliva total score;   Scores for sticky saliva during the day, assessed using the GRIX subscale;   Scores for sticky saliva during the night, assessed using the GRIX subscale;   Scores for xerostomia during the day, assessed using the GRIX subscale;   Scores for xerostomia during the night, assessed using the GRIX subscale;   Xerostomia total scores, assessed using the GRIX subscale;   QLQ-H&N35 scores
11 Unknown  N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
Conditions: Heart Failure, Congestive;   Kidney Failure, Chronic
Intervention: Drug: N-Acetylcysteine
Outcome Measures: Vascular function via non invasive ultrasound measured flow mediated dilatation;   Estimated glomerular filtration rate calculated with Cockroft Gault equation.;   Symptoms of heart failure;   Death;   Serum BNP (brain natriuretic peptide)
12 Recruiting Effectiveness of N-Acetylcysteine ​​on Preservation Solution During Liver Transplantation
Condition: Unspecified Complication of Liver Transplant
Interventions: Drug: N-Acetylcysteine;   Drug: Saline
Outcome Measures: The incidence of primary graft dysfunction and primary failure;   To assess the existence of side effects from the use of n-Acetylcysteine ​​on liver preservation solution usual.;   Reduction of postoperative renal disfunction;   Assess levels of glutathione stores achieved following administration of NAC;   Histological changes
13 Recruiting N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Conditions: Diabetic Nephropathies;   Proteinuria;   Oxidative Stress
Interventions: Dietary Supplement: N-Acetylcysteine;   Dietary Supplement: silibin;   Dietary Supplement: high-dose silibin;   Dietary Supplement: N-Acetylcysteine placebo;   Dietary Supplement: silibin placebo
Outcome Measures: Urinary Albumin excretion;   urinary alpha-1 microglobulin excretion;   urinary C-C-chemokines excretion;   peripheral blood monocyte glutathione content;   tolerance and safety
14 Recruiting N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
Conditions: Chronic Obstructive Pulmonary Disease;   Chronic Bronchitis
Interventions: Drug: N-Acetylcysteine;   Drug: Identical placebo pills twice daily for 8 weeks
Outcome Measure: Changes in the Saint George's Respiratory Questionnaire (SGRQ)
15 Unknown  Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)
Condition: Disorder Related to Renal Transplantation
Intervention: Drug: N-acetyl Cysteine
Outcome Measures: renal function biomarkers (IL18, NGAL)difference between study and control group in 4 and 24 hr after transplantation;   dialysis
16 Unknown  Effects of N-Acetylcysteine on Low T3 Syndrome
Conditions: Acute Myocardial Infarction;   Euthyroid Sick Syndrome;   Ischemic Heart Disease
Intervention: Drug: N-Acetylcysteine
Outcome Measure: Change from baseline in serum T3 levels at 48 hours
17 Unknown  N-Acetylcysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Mesothelioma
Interventions: Drug: N-Acetylcysteine;   Drug: Placebo
Outcome Measures: The occurrence of peripheral neuropathy: with the peripheral neuropathy score (PNP-score) and the electrophysiological measurements. If no EMG is available, then audiometric measurements will be taken into account.;   haematological abnormalities;   creatinine clearance.;   liver chemistry abnormalities;   Karnofski Performance Score;   Quality of life
18 Recruiting N-Acetylcysteine in TTP
Conditions: Thrombotic Thrombocytopenia Purpura;   TTP
Intervention: Drug: N-Acetylcysteine
Outcome Measures: Changes in platelet count;   Laboratory measures of VWF activity;   Laboratory measures of ADAMTS13 activity;   Laboratory measures of red blood cell (RBC) hemolysis and oxidation;   Safety of NAC infusion
19 Unknown  Evaluating N-Acetylcysteine in CTD-ILD Treatment
Conditions: Interstitial Lung Disease;   Connective Tissue Disease
Intervention: Drug: N-Acetylcysteine
Outcome Measures: Assess the tolerability and safety of N-Acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).;   Evaluate the efficacy of NAC in patients with CTD-ILD.;   Assess serum matrix metalloproteinase (MMP) levels as a potential biomarker.
20 Unknown  N-Acetylcysteine for Patients With COPD and ChronicBronchitis
Conditions: Chronic Obstructive Pulmonary Disease;   Chronic Bronchitis
Interventions: Drug: N-Acetylcysteine;   Drug: Oral Acetylcysteine
Outcome Measure: Changes in the St. George's Respiratory Questionnaire

These studies may lead to new treatments and are adding insight into Acetylcysteine etiology and treatment.

A major focus of Acetylcysteine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Acetylcysteine